TNF-α and IFN-s-dependent muscle decay is linked to NF-κB- and STAT-1 α-stimulated Atrogin1 and MuRF1 genes in C2C12 myotubes

Mediators of Inflammation

Volumn 2013, Issue , 2013, Pages

  Pijet, Barbara ^a   Pijet, Maja ^a   Litwiniuk, Anna ^a   Gajewska, Małgorzata ^a   Paja̧k, Beata ^b   Orzechowski, Arkadiusz ^a,b  

^a WARSAW UNIVERSITY OF LIFE SCIENCES   (Poland)

^b MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ATROGIN 1; CURCUMIN; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERFERON; JANUS KINASE; MUSCLE RING FINGER 1 PROTEIN; MYOSIN HEAVY CHAIN ALPHA; MYOSIN HEAVY CHAIN II ALPHA; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; STAT 1 ALPHA PROTEIN; STAT1 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN PROTEIN; UNCLASSIFIED DRUG; FBXO32 PROTEIN, MOUSE; GAMMA INTERFERON ACTIVATION FACTOR; INTERFERON STIMULATED GENE FACTOR 3; MUSCLE PROTEIN; MYOSIN HEAVY CHAIN; PROTEASOME; TRADD PROTEIN, MOUSE; TRIM63 PROTEIN, MOUSE; UBIQUITIN PROTEIN LIGASE;

ANIMAL CELL; ARTICLE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE ACTIVITY; MITOGENICITY; MYOBLAST; MYOTUBE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; CELL LINE; CELL SURVIVAL; DRUG EFFECT; GENETICS; METABOLISM; MOUSE; PHYSIOLOGY; SKELETAL MUSCLE;

ANIMALS; CELL LINE; CELL SURVIVAL; CURCUMIN; INSULIN; INTERFERON-STIMULATED GENE FACTOR 3; INTERFERONS; JANUS KINASES; MICE; MUSCLE FIBERS, SKELETAL; MUSCLE PROTEINS; MUSCLE, SKELETAL; MYOSIN HEAVY CHAINS; NF-KAPPA B; PROTEASOME ENDOPEPTIDASE COMPLEX; SKP CULLIN F-BOX PROTEIN LIGASES; TNF RECEPTOR-ASSOCIATED DEATH DOMAIN PROTEIN; TUMOR NECROSIS FACTOR-ALPHA; UBIQUITIN-PROTEIN LIGASES;

EID: 84893852674     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2013/171437     Document Type: Article

References (52)

1. Evans W. J., Morley J. E., Argilés J., Bales C., Baracos V., Guttridge D., Jatoi A., Kalantar-Zadeh K., Lochs H., Mantovani G., Marks D., Mitch W. E., Muscaritoli M., Najand A., Ponikowski P., Rossi Fanelli F., Schambelan M., Schols A., Schuster M., Thomas D., Wolfe R., Anker S. D., Cachexia: a new definition. Clinical Nutrition 2008 27 6 793 799 2-s2.0-55749085001 10.1016/j.clnu.2008.06.013
2. Tisdale M. J., Mechanisms of cancer cachexia. Physiological Reviews 2009 89 2 381 410 2-s2.0-67649982995 10.1152/physrev.00016.2008
3. Hasselgren P., Fischer J. E., Muscle cachexia: current concepts of intracellular mechanisms and molecular regulation. Annals of Surgery 2001 233 1 9 17 2-s2.0-0035164533 10.1097/00000658-200101000-00003 (Pubitemid 32042769)
4. Cheshire J. L., Baldwin A. S. Jr., Synergistic activation of NF-κB by tumor necrosis factor alpha and gamma interferon via enhanced I B α degradation and de novo I B β degradation. Molecular and Cellular Biology 1997 17 11 6746 6754 2-s2.0-0030764347 (Pubitemid 27451222)
5. Guttridge D. C., Mayo M. W., Madrid L. V., Wang C.-Y., Baldwin A.S. J. Jr., NF-κB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 2000 289 5488 2363 2366 2-s2.0-0034730251 10.1126/science.289.5488.2363
6. Acharyya S., Ladner K. J., Nelsen L. L., Damrauer J., Reiser P. J., Swoap S., Guttridge D. C., Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. The Journal of Clinical Investigation 2004 114 3 370 378 2-s2.0-4043154377 10.1172/JCI200420174 (Pubitemid 39071609)
7. Wheeler M. T., Snyder E. C., Patterson M. N., Swoap S. J., An E-box within the MHC IIB gene is bound by MyoD and is required for gene expression in fast muscle. American Journal of Physiology-Cell Physiology 1999 276 5 C1069 C1078 2-s2.0-0033023377 (Pubitemid 29244660)
8. Dehoux M., Gobier C., Lause P., Bertrand L., Ketelslegers J., Thissen J., IGF-I does not prevent myotube atrophy caused by proinflammatory cytokines despite activation of Akt/Foxo and GSK-3 β pathways and inhibition of atrogin-1 mRNA. American Journal of Physiology-Endocrinology and Metabolism 2007 292 1 E145 E150 2-s2.0-33846072478 10.1152/ajpendo.00085.2006 (Pubitemid 46070110)
9. Cong H., Sun L., Liu C., Tien P., Inhibition of atrogin-1/MAFbx expression by adenovirus-delivered small hairpin RNAs attenuates muscle atrophy in fasting mice. Human Gene Therapy 2011 22 3 313 324 2-s2.0-79952664481 10.1089/hum.2010.057
10. Ebert S. M., Dyle M. C., Kunkel S. D., Bullard S. A., Bongers K. L., Fox D. K., Dierdorff J. M., Foster E. D., Adams C. M., Stress-induced skeletal muscle Gadd45a expression reprograms myonuclei and causes muscle atrophy. The Journal of Biological Chemistry 2012 287 27290 27301
11. Fanzani A., Conraads V. M., Penna F., Martinet W., Molecular and cellular mechanisms of skeletal muscle atrophy: an update. Journal of Cachexia, Sarcopenia and Muscle 2012 3 163 179
12. Sakuma K., Yamaguchi A., Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass. Journal of Cachexia, Sarcopenia and Muscle 2012 3 77 94
13. Bonetto A., Aydogdu T., Jin X., Zhang Z., Zhan R., Puzis L., Koniaris L. G., Zimmers T. A., JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. American Journal of Physiology-Endocrinology and Metabolism 2011 303 E410 E421
14. Bonetto A., Aydogdu T., Kunzevitzky N., Guttridge D. C., Khuri S., Koniaris L. G., Zimmers T. A., STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS ONE 2012 6 7 17 2-s2.0-79960611800 e22538
15. De Larichaudy J., Zufferli A., Serra F., Isidori A. M., Naro F., Dessalle K., Desgeorges M., Piraud M., Cheillan D., Vidal H., Lefai E., Némoz G., TNF- α-and tumor-induced skeletal muscle atrophy involves sphingolipid metabolism. Skeletal Muscle 2012 2 2 19
16. Melstrom L. G., Melstrom K. A. Jr., Ding X.-Z., Adrian T. E., Mechanisms of skeletal muscle degradation and its therapy in cancer cachexia. Histology and Histopathology 2007 22 7-9 805 814 2-s2.0-34248584713 (Pubitemid 47034146)
17. Zhou X., Wang J. L., Lu J., Song Y., Kwak K. S., Jiao Q., Rosenfeld R., Chen Q., Boone T., Simonet W. S., Lacey D. L., Goldberg A. L., Han H. Q., Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell 2011 142 4 531 543 2-s2.0-77955642517
18. Karin M., Lin A., NF-κB at the crossroads of life and death. Nature Immunology 2002 3 3 221 227 2-s2.0-0036009115 10.1038/ni0302-221 (Pubitemid 34213423)
19. Cai D., Frantz J. D., Tawa N. E. Jr., Melendez P. A., Oh B., Lidov H. G. W., Hasselgren P., Frontera W. R., Lee J., Glass D. J., Shoelson S. E., IKK β/NF-κB activation causes severe muscle wasting in mice. Cell 2004 119 2 285 298 2-s2.0-5444262078 10.1016/j.cell.2004.09.027 (Pubitemid 39360909)
20. Mourkioti F., Rosenthal N., NF-κB signaling in skeletal muscle: prospects for intervention in muscle diseases. Journal of Molecular Medicine 2008 86 7 747 759 2-s2.0-46149126918 10.1007/s00109-008-0308-4
21. Reed S. A., Senf S. M., Cornwell E. W., Kandarian S. C., Judge A. R., Inhibition of IkappaB kinase alpha (IKK α) or IKKbeta (IKK β) plus forkhead box O (Foxo) abolishes skeletal muscle atrophy. Biochemical and Biophysical Research Communications 2011 405 3 491 496 2-s2.0-79951581392 10.1016/j.bbrc.2011.01.059
22. Yaffe D., Saxel O., Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. Nature 1977 270 5639 725 727 2-s2.0-0017759258 (Pubitemid 8239246)
23. Jacobson M. D., Burne J. F., Raff M. C., Programmed cell death and Bcl-2 protection in the absence of a nucleus. The EMBO Journal 1994 13 8 1899 1910 2-s2.0-0028268215 (Pubitemid 24124523)
24. Bradford M. M., A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Analytical Biochemistry 1976 72 1-2 248 254 2-s2.0-0017184389
25. Argilés J. M., Busquets S., Toledo M., López-Soriano F. J., The role of cytokines in cancer cachexia. Current Opinion in Supportive and Palliative Care 2009 3 4 263 268 2-s2.0-74549129085 10.1097/SPC.0b013e3283311d09
26. Morley J. E., Thomas D. R., Wilson M. G., Cachexia: pathophysiology and clinical relevance. American Journal of Clinical Nutrition 2006 83 4 735 743 2-s2.0-33646674302 (Pubitemid 44713134)
27. Zimmers T. A., Davies M. V., Koniaris L. G., Haynes P., Esquela A. F., Tomkinson K. N., McPherron A. C., Wolfman N. M., Lee S., Induction of cachexia in mice by systemically administered myostatin. Science 2002 296 5572 1486 1488 2-s2.0-0037165983 10.1126/science.1069525 (Pubitemid 34553097)
28. Busquets S., Toledo M., Orpí M., Massa D., Porta M., Capdevila E., Padilla N., Frailis V., López-Soriano F. J., Han H. Q., Argilés J. M., Myostatin blockage using actRIIB antagonism in mice bearing the Lewis lung carcinoma results in the improvement of muscle wasting and physical performance. Journal of Cachexia, Sarcopenia and Muscle 2012 3 37 43
29. Pijet M., Pijet B., Litwiniuk A., Paja̧k B., Gajkowska B., Orzechowski A., Leptin impairs myogenesis in C2C12 cells through JAK/STAT and MEK signaling pathways. Cytokine 2013 61 445 454
30. Spangenburg E. E., Booth F. W., Multiple signaling pathways mediate LIF-induced skeletal muscle satellite cell proliferation. American Journal of Physiology-Cell Physiology 2002 283 1 C204 C211 2-s2.0-0036088601 (Pubitemid 34670564)
31. Argiles J. M., Bosquets S., Lopez-Soriano F. J., Cytokines in the pathogenesis of cancer cachexia. Current Opinion in Clinical Nutrition and Metabolic Care 2003 6 401 406 (Pubitemid 40684591)
32. Buck M., Chojkier M., Muscle wasting and dedifferentiation induced by oxidative stress in a murine model of cachexia is prevented by inhibitors of nitric oxide synthesis and antioxidants. The EMBO Journal 1996 20 6712 6723
33. Di Marco S., Mazroui R., Dallaire P., Chittur S., Tenenbaum S. A., Radzioch D., Marette A., Gallouzi I., NF-κB-mediated MyoD decay during muscle wasting requires nitric oxide synthase mRNA stabilization, HuR protein, and nitric oxide release. Molecular and Cellular Biology 2005 25 15 6533 6545 2-s2.0-22544452988 10.1128/MCB.25.15.6533-6545.2005 (Pubitemid 41023228)
34. Guttridge D. C., Albanese C., Reuther J. Y., Pestell R. G., Baldwin A. S. Jr., NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Molecular and Cellular Biology 1999 19 8 5785 5799 2-s2.0-0032588186 (Pubitemid 29339933)
35. Bhatnagar S., Panguluri S. K., Gupta S. K., Dahiya S., Lundy R. F., Kumar A., Tumor necrosis factor- α regulates distinct molecular pathways and gene networks in cultured skeletal muscle cells. PLoS ONE 2010 5 10 2-s2.0-78149443851 10.1371/journal.pone.0013262 e13262
36. Lu A., Proto J. D., Guo L., Tang Y., Lavasani M., Tilstra J. S., Niedernhofer L. J., Wang B., Guttridge D. C., Robbins P. D., Huard J., NF-κB negatively impacts the myogenic potential of muscle-derived stem cells. Molecular Therapy 2012 20 3 661 668 2-s2.0-84857784709 10.1038/mt.2011.261
37. Giampietri C., Petrungaro S., Coluccia P., Antonangeli F., Giannakakis K., Faraggiana T., Filippini A., Cossu G., Ziparo E., c-flip overexpression affects satellite cell proliferation and promotes skeletal muscle aging. Cell Death and Disease 2010 1 4, article e38 2-s2.0-79959947323 10.1038/cddis.2010.17
38. Kataoka T., Budd R. C., Holler N., Thome M., Martinon F., Irmler M., Burns K., Hahne M., Kennedy N., Kovacsovics M., Tschopp J., The caspase-8 inhibitor FLIP promotes activation of NF-κB and Erk signaling pathways. Current Biology 2000 10 11 640 648 2-s2.0-18744425429 10.1016/S0960-9822(00) 00512-1 (Pubitemid 30354699)
39. Dunlop R. J., Campbell C. W., Cytokines and advanced cancer. Journal of Pain and Symptom Management 2000 20 3 214 232 2-s2.0-0033835250 10.1016/S0885-3924(00)00199-8
40. Jackman R. W., Kandarian S. C., The molecular basis of skeletal muscle atrophy. American Journal of Physiology-Cell Physiology 2004 287 4 C834 C843 2-s2.0-4544235672 10.1152/ajpcell.00579.2003 (Pubitemid 39238306)
41. Wang Y., Wu T. R., Cai S., Welte T., Chin Y. E., Stat1 as a component of tumor necrosis factor alpha receptor 1-TRADD signaling complex to inhibit NF-κB activation. Molecular and Cellular Biology 2000 20 13 4505 4512 2-s2.0-0034130327 10.1128/MCB.20.13.4505-4512.2000 (Pubitemid 30396098)
42. Wesemann D. R., Benveniste E. N., STAT-1 α and IFN- γ as modulators of TNF- α signaling in macrophages: regulation and functional implications of the TNF receptor 1:STAT-1 α complex. Journal of Immunology 2003 171 10 5313 5319 2-s2.0-0242662865 (Pubitemid 37432816)
43. Wesemann D. R., Qin H., Kokorina N., Benveniste E. N., TRADD interacts with STAT1- α and influences interferon- γ signaling. Nature Immunology 2004 5 2 199 207 2-s2.0-1142275268 10.1038/ni1025 (Pubitemid 38208362)
44. Pajak B., Orzechowski A., IFN-alpha competes with TNF-alpha for STAT-1alpha; molecular basis for immune escape of human colon adenocarcinoma COLO 205 cells. Oncology Reports 2007 18 4 1039 1045 2-s2.0-38449105965
45. Mitsiades C. S., Mitsiades N., Poulaki V., Schlossman R., Akiyama M., Chauhan D., Hideshima T., Treon S. P., Munshi N. C., Richardson P. G., Anderson K. C., Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 2002 21 37 5673 5683 2-s2.0-0037158513 10.1038/sj.onc.1205664 (Pubitemid 35333000)
46. Jobin C., Bradham C. A., Russo M. P., Juma B., Narula A. S., Brenner D. A., Sartor R. B., Curcumin blocks cytokine-mediated NF-κB activation and proinflammatory gene expression by inhibiting inhibitory factor I- B kinase activity. Journal of Immunology 1999 163 6 3474 3483 2-s2.0-0033568674 (Pubitemid 29431852)
47. Kumar N. B., Kazi A., Smith T., Crocker T., Yu D., Reich R. R., Reddy K., Hastings S., Exterman M., Balducci L., Dalton K., Bepler G., Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment. Current Treatment Options in Oncology 2010 11 3-4 107 117 2-s2.0-79951882924 10.1007/s11864-010-0127-z
48. Bodine S. C., Latres E., Baumhueter S., Lai V. K.-M., Nunez L., Clarke B. A., Poueymirou W. T., Panaro F. J., Erqian Na E. N., Dharmarajan K., Pan Z.-Q., Valenzuela D. M., Dechiara T. M., Stitt T. N., Yancopoulos G. D., Glass D. J., Identification of ubiquitin ligases required for skeletal Muscle Atrophy. Science 2001 294 5547 1704 1708 2-s2.0-0035941020 10.1126/science.1065874 (Pubitemid 33104839)
49. Gomes M. D., Lecker S. H., Jagoe R. T., Navon A., Goldberg A. L., Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proceedings of the National Academy of Sciences of the United States of America 2001 98 25 14440 14445 2-s2.0-0035807969 10.1073/pnas.251541198 (Pubitemid 33121410)
50. Acharyya S., Guttridge D. C., Cancer cachexia signaling pathways continue to emerge yet much still points to the proteasome. Clinical Cancer Research 2007 13 5 1356 1361 2-s2.0-33947417337 10.1158/1078-0432.CCR-06-2307 (Pubitemid 46450422)
51. Tan Y., Peng X., Wang F., You Z., Dong Y., Wang S., Effects of tumor necrosis factor-alpha on the 26S proteasome and 19S regulator in skeletal muscle of severely scalded mice. Journal of Burn Care and Research 2006 27 2 226 233 2-s2.0-33745346649 (Pubitemid 43970330)
52. Pajak B., Orzechowska S., Pijet B., Pijet M., Pogorzelska A., Gajkowska B., Orzechowski A., Crossroads of cytokine signaling: the chase to stop muscle cachexia. Journal of Physiology and Pharmacology 2008 59 supplement 9 251 264 2-s2.0-64049106742